CR10287A - Derivados de octahidro -pirrolo [3,4-b]pirrol - Google Patents

Derivados de octahidro -pirrolo [3,4-b]pirrol

Info

Publication number
CR10287A
CR10287A CR10287A CR10287A CR10287A CR 10287 A CR10287 A CR 10287A CR 10287 A CR10287 A CR 10287A CR 10287 A CR10287 A CR 10287A CR 10287 A CR10287 A CR 10287A
Authority
CR
Costa Rica
Prior art keywords
octahidro
pirrol
pirrolo
derivatives
compounds
Prior art date
Application number
CR10287A
Other languages
English (en)
Inventor
Marlon Zhencowart
Chen Zhao
Minghua Sun
Lawrance Balck
Guo Zhu Zheng
Robert J Gregg
Geoff G Z Zhang
Ahmad Y Sheikh
Xiaochun Lou
Rodger F Henry
David M Barnes
Lawrence Kolaczkowski
Anthony R Haight
Sou-Jen Chang
Steven J Wittenberger
Michael G Fickes
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38325247&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10287(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of CR10287A publication Critical patent/CR10287A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

Derivados de octahidro-pirrolo[3,4-b]pirrol utiles para tratar condiciones o trastornos que se previenen o mejoran con ligandos del receptor de histamina-3. En la presente se divulgan compuestos, composiciones para hacerlos, y procesos para preparar dichos compuestos.
CR10287A 2006-02-24 2008-09-16 Derivados de octahidro -pirrolo [3,4-b]pirrol CR10287A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77650906P 2006-02-24 2006-02-24

Publications (1)

Publication Number Publication Date
CR10287A true CR10287A (es) 2008-12-10

Family

ID=38325247

Family Applications (2)

Application Number Title Priority Date Filing Date
CR10287A CR10287A (es) 2006-02-24 2008-09-16 Derivados de octahidro -pirrolo [3,4-b]pirrol
CR20140203A CR20140203A (es) 2006-02-24 2014-05-05 Derivados de octahidro-pirrolo (3,4-b) pirrol

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20140203A CR20140203A (es) 2006-02-24 2014-05-05 Derivados de octahidro-pirrolo (3,4-b) pirrol

Country Status (21)

Country Link
US (2) US7728031B2 (es)
EP (1) EP2001885A2 (es)
JP (1) JP5463038B2 (es)
KR (2) KR20080106295A (es)
CN (2) CN101415709A (es)
AU (1) AU2007220889B2 (es)
BR (1) BRPI0708258A2 (es)
CA (1) CA2641624A1 (es)
CR (2) CR10287A (es)
EC (1) ECSP088687A (es)
GT (1) GT200800166A (es)
IL (1) IL193270A0 (es)
MX (1) MX2008010805A (es)
MY (2) MY149513A (es)
NO (1) NO20084056L (es)
NZ (2) NZ595275A (es)
RU (1) RU2492172C2 (es)
SG (2) SG188878A1 (es)
TW (1) TWI389910B (es)
UA (1) UA97639C2 (es)
WO (1) WO2007100990A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2007004244A0 (en) 2005-05-10 2007-12-31 Intermune Inc Method of modulating stress-activated protein kinase system
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
EP2152270B1 (en) 2007-06-08 2015-03-04 Janssen Pharmaceutica, N.V. Piperidine/piperazine derivatives
JP5443342B2 (ja) 2007-06-08 2014-03-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピペリジン／ピペラジン誘導体
ES2483898T3 (es) 2007-06-08 2014-08-08 Janssen Pharmaceutica, N.V. Derivados de piperidina/piperazina
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101809021B (zh) * 2007-09-11 2013-04-24 雅培制药有限公司 八氢-吡咯并[3,4-b]吡咯n-氧化物
MX2010005650A (es) * 2007-11-21 2010-06-02 Abbott Lab Derivados de diazabicicloalcano substituidos con biarilo.
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
PE20100083A1 (es) 2008-06-05 2010-02-17 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
WO2010135470A1 (en) * 2009-05-19 2010-11-25 Intermune, Inc. Pifenidone derivatives for treating bronchial asthma
US8252801B1 (en) 2009-06-03 2012-08-28 Abbott Laboratories Treatment of schizophrenia and related disorders
WO2011068926A1 (en) * 2009-12-04 2011-06-09 Tetralogic Pharmaceuticals Corp. Iap inhibitors
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
GB201416351D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Heterocyclic derivatives

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS229067B1 (en) * 1981-08-20 1984-04-16 Svorad Stolc Medicinal preparation with antiarhythmic and supporting effect applied with hypoxia,and method of preparing active substance thereof
DE3906365A1 (de) 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
DE59009705D1 (de) * 1989-04-17 1995-11-02 Bayer Ag Verfahren zur Herstellung von 2,7-Diazabicyclo(3.3.0)octanen.
US6090820A (en) 1995-05-11 2000-07-18 Pharmacia & Upjohn Company Spirocyclic and bicyclic diazinyl and carbazinyl oxazolidinones
JP3204456B2 (ja) * 1995-12-21 2001-09-04 ファイザー・インコーポレーテッド ２，７―置換オクタヒドロ―ピロロ［１，２―ａ］ピラジン誘導体
PL198503B1 (pl) 1998-10-27 2008-06-30 Abbott Lab Związki pirydazynonowe, kompozycje farmaceutyczne je zawierające oraz ich zastosowanie
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
MY145722A (en) 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
JP4516717B2 (ja) 2000-07-13 2010-08-04 アボット・ラボラトリーズ ヒスタミン−３受容体リガンドとしての１，３−二置換ピロリジン及び１，３，３−三置換ピロリジン並びにそれらの治療的応用
WO2002006278A1 (en) 2000-07-17 2002-01-24 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
US6316475B1 (en) 2000-11-17 2001-11-13 Abbott Laboratories Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications
CA2436083A1 (en) 2001-02-08 2002-09-19 Schering Corporation Use of dual h3/m2 antagonists in the treatment of cognition deficit disorders
WO2002070523A1 (en) 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
CN100360130C (zh) * 2002-04-18 2008-01-09 先灵公司 用作组胺h3拮抗剂的1－(4－哌啶基)苯并咪唑酮
US20040092521A1 (en) * 2002-11-12 2004-05-13 Altenbach Robert J. Bicyclic-substituted amines as histamine-3 receptor ligands
EP1611441A4 (en) 2003-03-24 2006-08-09 Novascreen Biosciences Corp METHOD AND APPARATUS FOR DISCOVERING MEDICAMENTS
EP1633756B1 (en) 2003-04-09 2008-12-24 Biogen Idec MA Inc. A2a adenosine receptor antagonists
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
AU2004283461B2 (en) * 2003-10-15 2010-02-11 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
WO2005054194A1 (en) 2003-11-25 2005-06-16 Texcontor Etablissement A method for the preparation of (2s, 3ar, 7as)-octahydro-1h-indole-2-carboxylic acid as key intermediate in the preparation of trandolapril by reacting a cyclohexyl aziridine with a dialkyl malonate
WO2005054239A1 (en) * 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
WO2005056056A2 (en) 2003-12-15 2005-06-23 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
ATE437880T1 (de) 2004-02-04 2009-08-15 Neurosearch As Dimere azacyclische verbindungen und deren verwendung
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US20050245543A1 (en) * 2004-04-30 2005-11-03 Pfizer Inc Histamine-3 receptor antagonists
EP1771449A1 (en) * 2004-07-21 2007-04-11 Pfizer Products Incorporated Histamine-3 receptor antagonists
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0514018D0 (en) 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
US7745448B2 (en) * 2005-12-28 2010-06-29 Abbott Laboratories Inc. Crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanolate
US7727953B2 (en) * 2005-12-29 2010-06-01 Abbott Laboratories Inc. Crystalline form of a drug
RU2008136898A (ru) 2006-02-15 2010-03-20 Санофи-Авентис (Fr) Азациклил-замещенные арилдигидроизохинолиноны, способ их получения и их применение в качестве лекарственных средств
AU2007214708A1 (en) 2006-02-15 2007-08-23 Sanofi-Aventis Novel azacycly-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
WO2007110868A2 (en) 2006-03-28 2007-10-04 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
WO2008002683A2 (en) * 2006-06-28 2008-01-03 Teva Pharmaceutical Industries Ltd. Polymorphous forms of carvedilol phosphate
EP2035372A1 (en) 2006-06-29 2009-03-18 Arena Pharmaceuticals, Inc. Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
CA2661334C (en) 2006-08-23 2011-11-29 Pfizer Products Inc. Pyrimidone compounds as gsk-3 inhibitors
US20080119457A1 (en) 2006-08-24 2008-05-22 Serenex, Inc. Benzene, Pyridine, and Pyridazine Derivatives
WO2008041090A1 (en) 2006-10-06 2008-04-10 Pfizer Limited Malanin concentrating hormone receptor-1 antagonist pyridinones
WO2008059238A1 (en) 2006-11-17 2008-05-22 Astrazeneca Ab Benzenesulfonamide compounds as edg-1 antagonists useful in the treatment of cancer
AU2008223348A1 (en) * 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
CA2687721A1 (en) 2007-06-08 2008-12-18 Arena Pharmaceuticals, Inc. Crystalline forms of (r)-1-{2-[4'-(3-methoxy-propane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
CN101809021B (zh) 2007-09-11 2013-04-24 雅培制药有限公司 八氢-吡咯并[3,4-b]吡咯n-氧化物

Also Published As

Publication number Publication date
UA97639C2 (ru) 2012-03-12
US20100222358A1 (en) 2010-09-02
KR20140097612A (ko) 2014-08-06
RU2492172C2 (ru) 2013-09-10
NO20084056L (no) 2008-10-27
JP2009527578A (ja) 2009-07-30
TWI389910B (zh) 2013-03-21
RU2008137941A (ru) 2010-03-27
SG170033A1 (en) 2011-04-29
WO2007100990A2 (en) 2007-09-07
CN101415709A (zh) 2009-04-22
NZ595275A (en) 2013-07-26
KR20080106295A (ko) 2008-12-04
NZ570235A (en) 2011-10-28
US20070232612A1 (en) 2007-10-04
US7728031B2 (en) 2010-06-01
JP5463038B2 (ja) 2014-04-09
US8399468B2 (en) 2013-03-19
MY149513A (en) 2013-09-13
TW200808798A (en) 2008-02-16
CR20140203A (es) 2014-07-02
WO2007100990A3 (en) 2007-10-18
CN102827167A (zh) 2012-12-19
ECSP088687A (es) 2008-09-29
IL193270A0 (en) 2009-02-11
EP2001885A2 (en) 2008-12-17
MX2008010805A (es) 2008-09-01
BRPI0708258A2 (pt) 2011-05-24
CA2641624A1 (en) 2007-09-07
AU2007220889B2 (en) 2012-04-12
GT200800166A (es) 2009-01-21
SG188878A1 (en) 2013-04-30
AU2007220889A1 (en) 2007-09-07
MY152992A (en) 2014-12-31

Similar Documents

Publication Publication Date Title
ECSP088687A (es) Derivados de octahidro-pirrolo[3,4-b]pirrol
CY1117743T1 (el) Διυποκατεστημενα οκταϋδροπυρρολο [3,4-c]πυρρολια ως ρυθμιστες υποδοχεα ορεξινης
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
BRPI0811617A2 (pt) derivados de primidina e composições como inibidores de c-kit e pdgfr quinase.
CL2007002188A1 (es) Compuestos derivados de heteroarilaminas; procedimiento de preparacion; composicion farmceutica; y uso del compuesto para tratar el crecimiento celular anormal.
CL2008001897A1 (es) Proceso para la preparacion de 3-halometil-1-metil-1h-pirazol, utiles como intermediario en la produccion de fungicidas; compuestos derivados de 3-halometil-1-metil-1h-pirazol.
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
MY152283A (en) Polo-like kinase inhibitirs
MX2009003650A (es) Nuevos imidazotiazoles e imidazoxazoles.
SV2010003463A (es) Compuestos organicos
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
CL2011001947A1 (es) Compuestos derivados de fenil-{1,2,4}triazolo[1,5-a]piridin-fenilamino sustituidos, inhibidores de cinasa; utiles para tratar trastornos asociados con la permeabilidad vascular.
DOP2010000062A (es) Derivados de ciclopropilamida
MX2009006170A (es) Compuestos y composiciones como inhibidores de cinasa.
SV2006002218A (es) Fenilaminotiazoles sustituidos y su uso ref.bhc041280-sv
ECSP078011A (es) DERIVADOS DE PIRIDO[2,3-d]PIRIMIDINA, SU PREPARACION, SU APLICACION EN TERAPEUTICA
ECSP099046A (es) Derivados ciclopropil amina
NI200700318A (es) Benzocicloheptapiridinas como inhibidores de la tirosina quinasa de receptor met
TNSN08496A1 (en) Aminothiazoles and their uses
ECSP088472A (es) Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento
ECSP088176A (es) Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6
CL2008001837A1 (es) Uso de compuestos derivados de cinolin-3-carboxamida en el tratamiento de la esquizofrenia.
CL2008002377A1 (es) Procedimiento de preparacion de compuestos derivados de 3-piperidin-4-il-1,3,4,5-tetrahidro-benzo[d][1,3]diazepin-2-ona; compuestos intermediarios; y su procedimiento de preparacion.
DE602008002598D1 (en) Cyclohexylderivate
UY29756A1 (es) Derivados de 5-piridazinil-1-azabiciclo(3.2.1) octano, su preparación y su aplicación en terapéutica.